Valproate

Overview

Valproate (valproic acid, VPA, sodium valproate, or valproate semisodium) is a medication primarily used to treat epilepsy and as a mood stabilizer in the treatment of bipolar disorder. It is useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. It can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.[1] WP

Common side effects of valproate include nausea, vomiting, somnolence, and dry mouth. Serious side effects can include liver failure, and regular monitoring of liver function tests is therefore recommended. Other serious risks include pancreatitis and an increased suicide risk.[1] WP

Valproate is known to cause serious abnormalities or birth defects in the fetus if taken during pregnancy, and is contra-indicated for women of childbearing age unless the drug is essential to their medical condition and the person is also prescribed a contraceptive. Reproductive warnings have also been issued for men using the drug.[1–5] WP

Valproate is restricted in the United Kingdom for both women and men under age 55 due to teratogenicity in pregnant women and fertility problems in men. It is also restricted in the European Union. The United States Food and Drug Administration has indicated a black box warning given the frequency and severity of the side effects and teratogenicity. Additionally, there is also a black box warning due to risk of hepatotoxicity and pancreatitis.[4][6–9] WP

Valproate has been in use in Japan for the prophylaxis of migraine since 2011. It is approved as an antimanic and antiseizure in Japan as well. In UK, valproate is approved for bipolar mania and epilepsy, and both valproate and divalproex are approved, although divalproex sodium is known as valproate semisodium.[10–13] WP

Valproate's precise mechanism of action is unclear. Proposed mechanisms include affecting GABA levels, blocking voltage-gated sodium channels, inhibiting histone deacetylases, and increasing LEF1. Valproic acid is a branched short-chain fatty acid (SCFA), a derivative of valeric acid.[1][14–17] WP

Valproate was originally synthesized in 1881 and came into medical use in 1962. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 160th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[1][18–21] WP

Uses, dosage and effects

Medical uses

Valproate or valproic acid is used primarily to treat epilepsy and bipolar disorder.[22] WP

Epilepsy

Valproate has a broad spectrum of anticonvulsant activity, although it is primarily used as a first-line treatment for tonic–clonic seizures, absence seizures and myoclonic seizures and as a second-line treatment for partial seizures and infantile spasms. It has also been successfully given intravenously to treat status epilepticus.[22–25] WP

In the US, valproic acid is also prescribed as an anti-epileptic drug indicated for the treatment of manic episodes associated with bipolar disorder; monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in people with multiple seizure types that include absence seizures.[4][26] WP

Psychiatric disorders

Valproate products are used to treat manic or mixed episodes of bipolar disorder.[27][28] WP

A 2016 systematic review compared the efficacy of valproate as an add-on for people with schizophrenia:[29] WP⚠ A table follows this text in the source and is not copied here. Open the source to see it.

Other uses

Based upon five case reports, valproic acid may have efficacy in controlling the symptoms of the dopamine dysregulation syndrome that arise from the treatment of Parkinson's disease with levodopa.[30][31][32] WP

Valproate is not commonly used to prevent or treat migraine headaches, but it may be prescribed if other medications are not effective.[33] WP

The medication has been tested in the treatment of AIDS and cancer, owing to its histone-deacetylase-inhibiting effects. It has cardioprotective, kidney protective, antiinflammatory, and antimicrobial effects.[34] WP

Off-label uses

In 2012, pharmaceutical company Abbott paid $1.6 billion in fines to US federal and state governments for illegal promotion of off-label uses for Depakote, including the sedation of elderly nursing home residents.[35][36] WP

Some studies have suggested that valproate may reopen the critical period for learning absolute pitch and possibly other skills such as language.[37][38] WP

Risks and side effects

Contraindications

Contraindications include: WP

• Pre-existing acute or chronic liver dysfunction or family history of severe liver inflammation (hepatitis), particularly medicine related.[39] WP
• Pregnancy 11% risk of birth defects and 30-40% risk of neuro-developmental disabilities which can be permanent[40] WP
• Known hypersensitivity to valproate or any of the ingredients used in the preparation[39] WP
• Urea cycle disorders[39] WP
• Hepatic porphyria[39] WP
• Hepatotoxicity[39] WP
• Mitochondrial disease[39] WP
• Pancreatitis[39] WP
• Porphyria[41] WP

Adverse effects

Most common adverse effects include:[4] WP

• Nausea (22%)[4] WP
• Drowsiness (19%)[4] WP
• Dizziness (12%)[4] WP
• Vomiting (12%)[4] WP
• Weakness (10%)[4] WP

Serious adverse effects include:[4] WP

• Bleeding[4] WP
• Low blood platelets[4] WP
• Encephalopathy[4] WP
• Suicidal behavior and thoughts[4] WP
• Low body temperature[4] WP

Valproic acid has a black box warning for hepatotoxicity, pancreatitis, and fetal abnormalities.[4] WP

There is evidence that valproic acid may cause premature growth plate ossification in children and adolescents, resulting in decreased height. Valproic acid can also cause mydriasis, a dilation of the pupils. There is evidence that shows valproic acid may increase the chance of Polyendocrine metabolic ovarian syndrome (PMOS) in women with epilepsy or bipolar disorder. Studies have shown this risk of PMOS is higher in women with epilepsy compared to those with bipolar disorder. Weight gain is also possible. Valproic acid may decrease platelets in proportion to its dosage, particularly in women and the elderly.[42–48] WP

Pregnancy

Valproate is a teratogen. Teratogens can cause birth defects. Valproate is restricted for all women under age 55 in the United Kingdom and European Union. It has a black box warning for pregnancy in the United States.[6][49][50] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

There are also restrictions for men. Children fathered by men taking valproate have a higher risk of neurodevelopmental disorders. Valproate is restricted for men under age 55 in the United Kingdom and European Union. The restrictions require two specialists to agree that there is no other effective or tolerated treatment for the patient.[6][51] WP

Elderly

Valproate may cause increased somnolence in the elderly. In a trial of valproate in elderly patients with dementia, a significantly higher portion of valproate patients had somnolence compared to placebo. In approximately one-half of such patients, there was associated reduced nutritional intake and weight loss.[4] WP

Overdose

Excessive amounts of valproic acid can result in somnolence, tremor, stupor, respiratory depression, coma, metabolic acidosis, and death. In general, serum or plasma valproic acid concentrations are in a range of 20–100 mg/L during controlled therapy, but may reach 150–1500 mg/L following acute poisoning. Monitoring of the serum level is often accomplished using commercial immunoassay techniques, although some laboratories employ gas or liquid chromatography. In contrast to other antiepileptic drugs, at present there is little favorable evidence for salivary therapeutic drug monitoring. Salivary levels of valproic acid correlate poorly with serum levels, partly due to valproate's weak acid property (pKa of 4.9).[52][53] WP

In severe intoxication, hemoperfusion or hemofiltration can be an effective means of hastening elimination of the drug from the body. Supportive therapy should be given to all patients experiencing an overdose and urine output should be monitored. Supplemental L-carnitine is indicated in patients having an acute overdose and also prophylactically in high risk patients. Acetyl-L-carnitine lowers hyperammonemia less markedly than L-carnitine.[4][54–58] WP

Interactions

Interactions

Valproate inhibits CYP2C9, glucuronyl transferase, and epoxide hydrolase and is highly protein bound and hence may interact with drugs that are substrates for any of these enzymes or are highly protein bound themselves. It may also potentiate the CNS depressant effects of alcohol. It should not be given in conjunction with other antiepileptics due to the potential for reduced clearance of other antiepileptics (including carbamazepine, lamotrigine, phenytoin and phenobarbital) and itself. It may also interact with:[4][39][59] WP

• Aspirin: may increase valproate concentrations. May also interfere with valproate's metabolism.[4][39][59] WP
• Benzodiazepines: may cause CNS depression and there are possible pharmacokinetic interactions.[4][39][59] WP
• Carbapenem antibiotics: reduce valproate levels, potentially leading to seizures.[4][39][59] WP
• Cimetidine: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations.[4][39][59] WP
• Erythromycin: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations.[4][39][59] WP
• Ethosuximide: valproate may increase ethosuximide concentrations and lead to toxicity.[4][39][59] WP
• Felbamate: may increase plasma concentrations of valproate.[4][39][59] WP
• Mefloquine: may increase valproate metabolism combined with the direct epileptogenic effects of mefloquine.[4][39][59] WP
• Oral contraceptives: may reduce plasma concentrations of valproate.[4][39][59] WP
• Primidone: may accelerate metabolism of valproate, leading to a decline of serum levels and potential breakthrough seizure.[4][39][59] WP
• Rifampicin: increases the clearance of valproate, leading to decreased valproate concentrations.[4][39][59] WP
• Warfarin: valproate may increase free warfarin concentration and prolong bleeding time.[4][39][59] WP
• Zidovudine: valproate may increase zidovudine serum concentration and lead to toxicity.[4][39][59] WP

Pharmacology

Pharmacodynamics

Although the mechanism of action of valproate is not fully understood, traditionally, its anticonvulsant effect has been attributed to the blockade of voltage-gated sodium channels and increased brain levels of the inhibitory synaptic neurotransmitter gamma-aminobutyric acid (GABA). The GABAergic effect is also believed to contribute towards the anti-manic properties of valproate. In animals, sodium valproate raises cerebral and cerebellar levels of GABA, possibly by inhibiting GABA degradative enzymes, such as GABA transaminase, succinate-semialdehyde dehydrogenase and by inhibiting the re-uptake of GABA by neuronal cells. Prevention of neurotransmitter-induced hyperexcitability of nerve cells via Kv7.2 channel and AKAP5 may also contribute to its mechanism. Valproate has been shown to protect against a seizure-induced reduction in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) as a potential therapeutic mechanism.[39][60][61] WP⚠ A table follows this text in the source and is not copied here. Open the source to see it.

Valproate is a weak or low-potency histone deacetylase inhibitor, specifically of the class I HDAC1, HDAC2, HDAC3, and HDAC8, but not of other HDACs. Earlier studies found a wide range of inhibitory potencies of valproate against HDACs, ranging from low micromolar to millimolar concentrations, but subsequent work with improved methodology has supported greater inhibitory potencies, with IC₅₀ (half-maximal inhibitory concentration) values in the range of 36 to 219 μM for the class I HDACs. For comparison, valproate was found to be 4- to 46-fold less potent in inhibiting the class I HDACs relative to butyric acid (butyrate). By inhibiting HDACs, valproate promotes more transcriptionally active chromatin structures, that is it exerts an epigenetic effect. This has been proven in mice: Valproic acid induced histone hyperacetylation had brain function effects on the next generation of mice through changes in sperm DNA methylation. Intermediate molecules include VEGF, BDNF, and GDNF.[62–67] WP

Endocrine actions

Valproic acid has been found to be an antagonist of the androgen and progesterone receptors, and hence as a nonsteroidal antiandrogen and antiprogestogen, at concentrations much lower than therapeutic serum levels. In addition, the drug has been identified as a potent aromatase inhibitor, and suppresses estrogen concentrations. These actions are likely to be involved in the reproductive endocrine disturbances seen with valproic acid treatment.[68][69] WP

Valproic acid has been found to directly stimulate androgen biosynthesis in the gonads via inhibition of histone deacetylases and has been associated with hyperandrogenism in women and increased 4-androstenedione levels in men. High rates of polycystic ovary syndrome and menstrual disorders have also been observed in women treated with valproic acid.[70][71] WP

Pharmacokinetics

Taken by mouth, valproate is rapidly and virtually completely absorbed from the gut. When in the bloodstream, 80–90% of the substance are bound to plasma proteins, mainly albumin. Protein binding is saturable: it decreases with increasing valproate concentration, low albumin concentrations, the patient's age, additional use of other drugs such as aspirin, as well as liver and kidney impairment. Concentrations in the cerebrospinal fluid and in breast milk are 1 to 10% of blood plasma concentrations.[72][73][74] WP

The vast majority of valproate metabolism occurs in the liver. Valproate is known to be metabolized by the cytochrome P450 enzymes CYP2A6, CYP2B6, CYP2C9, and CYP3A5. It is also known to be metabolized by the UDP-glucuronosyltransferase enzymes UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15. Some of the known metabolites of valproate by these enzymes and uncharacterized enzymes include (see image):[75] WP

• via glucuronidation (30–50%): valproic acid β-O-glucuronide[75] WP
• via beta oxidation (>40%): 2E-ene-valproic acid, 2Z-ene-valproic acid, 3-hydroxyvalproic acid, 3-oxovalproic acid[75] WP
• via omega oxidation: 5-hydroxyvalproic acid, 2-propyl-glutaric acid[75] WP
• some others: 3E-ene-valproic acid, 3Z-ene-valproic acid, 4-ene-valproic acid, 4-hydroxyvalproic acid[75] WP

All in all, over 20 metabolites are known.[72] WP

In adult patients taking valproate alone, 30–50% of an administered dose is excreted in urine as the glucuronide conjugate. The other major pathway in the metabolism of valproate is mitochondrial beta oxidation, which typically accounts for over 40% of an administered dose. Typically, less than 20% of an administered dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose of valproate is excreted unchanged (i.e., as valproate) in urine. Only a small amount is excreted via the faeces. Elimination half-life is 16±3 hours and can decrease to 4–9 hours when combined with enzyme inducers.[72][74][75] WP

Research

Research

A 2023 systematic review of the literature identified only one study in which valproate was evaluated in the treatment of seizures in infants aged 1 to 36 months. In a randomized control trial, valproate alone was found to show poorer outcomes for infants than valproate plus levetiracetam in terms of reduction of seizures, freedom from seizures, daily living ability, quality of life, and cognitive abilities.[76] WP

History

History

Valproic acid was first synthesized in 1882 by Beverly S. Burton as an analogue of valeric acid, found naturally in valerian. Valproic acid is a carboxylic acid, a clear liquid at room temperature. For many decades, its only use was in laboratories as a "metabolically inert" solvent for organic compounds. In 1962, the French researcher Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic acid while using it as a vehicle for a number of other compounds that were being screened for antiseizure activity. He found it prevented pentylenetetrazol-induced convulsions in laboratory rats. It was approved as an antiepileptic drug in 1967 in France and has become the most widely prescribed antiepileptic drug worldwide. Valproic acid has also been used for migraine prophylaxis and bipolar disorder.[77–80] WP

Legal status

Society and culture

Valproate is available as a generic medication.[1] WP

Restrictions

In 2024, for those under age 55, additional restrictions for valproate prescription have been imposed in the United Kingdom. Patients under 55 can still receive valproate, but need to obtain the permission of two specialists. The restrictions are, in women, due to the potential for birth defects in children born of women of childbearing age. In men, the restrictions are due to the potential for reversible male infertility, testicular problems, and the risks of neurodevelopmental conditions in children born to men taking valproate in the 3 months before conception. Similar restrictions have been imposed in the European Union for both women and men. In February 2026, a French man, Jean-Marc Laurent, filed what has been described as the first legal complaint related to paternal exposure to valproate, alleging that his child developed neurodevelopmental disorders after he had been treated with the drug prior to conception.[6][7][8][81–85] WP

Formulations

Valproate exists in two main molecular variants: sodium valproate and valproic acid without sodium (often implied by simply valproate). A mixture between these two is termed semisodium valproate. It is unclear whether there is any difference in efficacy between these variants, except from the fact that about 10% more mass of sodium valproate is needed than valproic acid without sodium to compensate for the sodium itself. In Europe, the US, and many other countries three variants of valproate are sold: valproic acid, sodium valproate and valproate semisodium also known as divalproex sodium, the latter is believed to have fewer gastrointestinal side-effects. Divalproex sodium tablets are a formulation comprising valproate sodium and valproic acid in a 1:1 molar relationship.[13][86][87] WP

Magnesium valproate is also available in China.[88][89] WP

Terminology

Valproate is a negative ion. The conjugate acid of valproate is valproic acid (VPA). Valproic acid is fully ionized into valproate at the physiologic pH of the human body, and valproate is the active form of the drug. Sodium valproate is the sodium salt of valproic acid. Divalproex sodium is a coordination complex composed of equal parts of valproic acid and sodium valproate.[90] WP

Brand names of valproic acid

Branded products include: WP

• Absenor (Orion Corporation Finland) WP
• Convulex (G.L. Pharma GmbH Austria) WP
• Depakene (Abbott Laboratories in US and Canada)[91] WP
• Depakin (Sanofi S.R.L. Italy)[92] WP
• Depakine (Sanofi Aventis France) WP
• Depakine (Sanofi Synthelabo Romania) WP
• Depalept (Sanofi Aventis Israel) WP
• Deprakine (Sanofi Aventis Finland) WP
• Encorate (Sun Pharmaceuticals India) WP
• Epilim (Sanofi Synthelabo Australia and South Africa) WP
• Stavzor (Noven Pharmaceuticals Inc.) WP
• Valcote (Abbott Laboratories Argentina) WP
• Valpakine (Sanofi Aventis Brazil) WP
• Orfiril (Desitin Arzneimittel GmbH Norway) WP

Portugal

• Tablets – Diplexil-R by Bial. WP

United states

• Intravenous injection – Depacon by Abbott Laboratories. WP
• Syrup – Depakene by Abbott Laboratories. (Note: Depakene capsules are valproic acid). WP
• Depakote tablets are a mixture of sodium valproate and valproic acid. WP
• Tablets – Eliaxim by Bial. WP

Australia

• Epilim Crushable Tablets Sanofi[93] WP
• Epilim Sugar Free Liquid Sanofi[93] WP
• Epilim Syrup Sanofi[93] WP
• Epilim Tablets Sanofi[93] WP
• Sodium Valproate Sandoz Tablets Sanofi WP
• Valpro Tablets Alphapharm WP
• Valproate Winthrop Tablets Sanofi WP
• Valprease tablets Sigma WP

New zealand

• Epilim by Sanofi-Aventis WP

All the above formulations are Pharmac-subsidised.[94] WP

UK

• Depakote Tablets (as in USA) WP
• Tablets – Orlept by Wockhardt and Epilim by Sanofi WP
• Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi WP
• Syrup – Epilim by Sanofi-Aventis WP
• Intravenous injection – Epilim Intravenous by Sanofi WP
• Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio. WP
• Enteric-coated tablets – Epilim EC200 by Sanofi is a 200 mg sodium valproate enteric-coated tablet. WP

UK only

• Capsules – Episenta prolonged release by Beacon WP
• Sachets – Episenta prolonged release by Beacon WP
• Intravenous solution for injection – Episenta solution for injection by Beacon WP

Germany, switzerland, norway, finland, sweden

• Tablets – Orfiril by Desitin Pharmaceuticals WP
• Intravenous injection – Orfiril IV by Desitin Pharmaceuticals WP

South africa

• Syrup – Convulex by Byk Madaus[95] WP
• Tablets – Epilim by Sanofi-synthelabo WP

Malaysia

• Tablets – Epilim (200 ENTERIC COATED) by Sanofi-Aventis WP
• Controlled release tablets – Epilim Chrono (500 CONTROLLED RELEASE) by Sanofi-Aventis[96] WP

Romania

• Companies are SANOFI-AVENTIS FRANCE, GEROT PHARMAZEUTIKA GMBH and DESITIN ARZNEIMITTEL GMBH WP
• Types are Syrup, Extended release mini tablets, Gastric resistant coated tablets, Gastric resistant soft capsules, Extended release capsules, Extended release tablets and Extended release coated tablets WP

Canada

• Intravenous injection – Epival or Epiject by Abbott Laboratories. WP
• Syrup – Depakene by Abbott Laboratories its generic formulations include Apo-Valproic and ratio-Valproic. WP

Japan

• Tablets – Depakene by Kyowa Hakko Kirin WP
• Extended release tablets – Depakene-R by Kyowa Hakko Kogyo and Selenica-R by Kowa WP
• Syrup – Depakene by Kyowa Hakko Kogyo WP

Europe

In much of Europe, Dépakine and Depakine Chrono (tablets) are equivalent to Epilim and Epilim Chrono above. WP

Taiwan

• Tablets (white round tablet) – Depakine by Sanofi Winthrop Industrie (France) WP

Iran

• Tablets – Epival 200 (enteric coated tablet) and Epival 500 (extended release tablet) by Iran Najo WP
• Slow release tablets – Depakine Chrono by Sanofi Winthrop Industrie (France) WP

Israel

Depalept and Depalept Chrono (extended release tablets) are equivalent to Epilim and Epilim Chrono above. Manufactured and distributed by Sanofi-Aventis. WP

India, russia and cis countries

• Valparin Chrono by Sanofi India WP
• Valprol CR by Intas Pharmaceutical (India) WP
• Encorate Chrono by Sun Pharmaceutical (India) WP
• Serven Chrono by Leeven APL Biotech (India) WP

Uruguay

• Tablets – DI DPA by Megalabs WP

Brand names of valproate semisodium

• Brazil – Depakote by Abbott Laboratories and Torval CR by Torrent do Brasil WP
• Canada – Epival by Abbott Laboratories WP
• Mexico – Epival and Epival ER (extended release) by Abbott Laboratories WP
• United Kingdom – Depakote (for psychiatric conditions) and Epilim (for epilepsy) by Sanofi-Aventis and generics WP
• United States – Depakote and Depakote ER (extended release) by Abbott Laboratories and generics[4] WP
• India – Valance and Valance OD by Abbott Healthcare Pvt Ltd, Divalid ER by Linux laboratories Pvt Ltd, Valex ER by Sigmund Promedica, Dicorate by Sun Pharma WP
• Germany – Ergenyl Chrono by Sanofi-Aventis and generics WP
• Chile – Valcote and Valcote ER by Abbott Laboratories WP
• France and other European countries – Depakote WP
• Peru – Divalprax by AC Farma Laboratories WP
• China – Diprate OD WP

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Valproic Acid. 24 November 2020
2. Other Valproate banned without the pregnancy prevention programme
3. Other Drug Safety Update - Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met. 24 April 2018
4. Journal / agency Depakote- divalproex sodium tablet, delayed release
5. Other Men on sodium valproate told to use contraception
6. Other Sodium valproate. 2024-10-01
7. Journal / agency Valproate and related substances - referral. 2013-10-11
8. Journal / agency Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures. 2024-01-12
9. Journal / agency FDA Information on Valproate
10. Other Appendix-II
11. Other Kusuri-no-Shiori(Drug Information Sheet)
12. Other Depakote® (divalproex sodium): bipolar mania & epilepsy
13. Journal / agency Fisher C, Broderick W. Sodium valproate or valproate semisodium: is there a difference in the treatment of bipolar disorder?. Psychiatric Bulletin. December 2003. doi:10.1192/pb.27.12.446
14. Journal / agency Owens MJ, Nemeroff CB. Pharmacology of valproate. Psychopharmacology Bulletin. 2003. PMID 14624230
15. Journal / agency Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, Altman RB, Klein TE. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenetics and Genomics. April 2013. doi:10.1097/FPC.0b013e32835ea0b2 · PMID 23407051 · PMC3696515
16. Harm reduction site Valproic acid. 29 July 2017
17. Journal / agency Santos R, Linker SB, Stern S, Mendes AP, Shokhirev MN, Erikson G, Randolph-Moore L, Racha V, Kim Y, Kelsoe JR, Bang AG, Alda M, Marchetto MC, Gage FH. Deficient LEF1 expression is associated with lithium resistance and hyperexcitability in neurons derived from bipolar disorder patients. Molecular Psychiatry. June 2021. doi:10.1038/s41380-020-00981-3 · PMID 33398088 · PMC9129103
18. Other Scott DF. The history of epileptic therapy: an account of how medication was developed. 1993
19. Other World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). 2023
20. Other Top 300 of 2023
21. Other Valproate Drug Usage Statistics, United States, 2014 - 2023
22. Other Australian Medicines Handbook. 2013
23. Journal / agency Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002. doi:10.2165/00023210-200216100-00003 · PMID 12269861
24. Journal / agency Olsen KB, Taubøll E, Gjerstad L. Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults. Acta Neurologica Scandinavica. Supplementum. 2007. doi:10.1111/j.1600-0404.2007.00847.x · PMID 17419829
25. Journal / agency Kwan SY. The role of intravenous valproate in convulsive status epilepticus in the future. Acta Neurologica Taiwanica. June 2010. PMID 20830628
26. Journal / agency Depakote ER- divalproex sodium tablet, extended release. 24 February 2023
27. Journal / agency Valproate Information
28. Journal / agency Jochim J, Rifkin-Zybutz RP, Geddes J, Cipriani A. Valproate for acute mania. The Cochrane Database of Systematic Reviews. October 2019. doi:10.1002/14651858.CD004052.pub2 · PMID 31621892 · PMC6797024
29. Journal / agency Wang Y, Xia J, Helfer B, Li C, Leucht S. Valproate for schizophrenia. The Cochrane Database of Systematic Reviews. November 2016. doi:10.1002/14651858.CD004028.pub4 · PMID 27884042 · PMC6734130
30. Journal / agency Pirritano D, Plastino M, Bosco D, Gallelli L, Siniscalchi A, De Sarro G. Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review. BioMed Research International. 2014. doi:10.1155/2014/728038 · PMID 25114917 · PMC4119624
31. Journal / agency Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease. Neurotherapeutics. January 2014. doi:10.1007/s13311-013-0238-x · PMID 24288035 · PMC3899484
32. Journal / agency Averbeck BB, O'Sullivan SS, Djamshidian A. Impulsive and compulsive behaviors in Parkinson's disease. Annual Review of Clinical Psychology. 2014. doi:10.1146/annurev-clinpsy-032813-153705 · PMID 24313567 · PMC4197852
33. Other Valproic acid: medicine used for bipolar disorder, epilepsy and migraine. 2018-09-27
34. Journal / agency Singh D, Gupta S, Verma I, Morsy MA, Nair AB, Ahmed AF. Hidden pharmacological activities of valproic acid: A new insight. Biomedicine & Pharmacotherapy. October 2021. doi:10.1016/j.biopha.2021.112021 · PMID 34463268
35. Other Aizenman NC. Abbott Laboratories to pay $1.6 billion over illegal marketing of Depakote. 7 May 2012
36. Other Schmidt M, Thomas K. Abbott settles marketing lawsuit. 8 May 2012
37. Journal / agency Gervain J, Vines BW, Chen LM, Seo RJ, Hensch TK, Werker JF, Young AH. Valproate reopens critical-period learning of absolute pitch. Frontiers in Systems Neuroscience. 2013. doi:10.3389/fnsys.2013.00102 · PMID 24348349 · PMC3848041
38. Other Thomson H. Learning drugs reawaken grown-up brain's inner child
39. Other Valpro sodium valproate. 16 December 2013
40. Other Update on MHRA review into safe use of valproate. 12 December 2022
41. Other Depakote 250mg Tablets - Summary of Product Characteristics. 28 November 2013
42. Journal / agency Wu S, Legido A, De Luca F. Effects of valproic acid on longitudinal bone growth. Journal of Child Neurology. January 2004. doi:10.1177/088307380401900105011 · PMID 15032379
43. Journal / agency Robinson PB, Harvey W, Belal MS. Inhibition of cartilage growth by the anticonvulsant drugs diphenylhydantoin and sodium valproate. British Journal of Experimental Pathology. February 1988. PMID 3126792 · PMC2013195
44. Journal / agency Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia. September 2001. doi:10.1046/j.1528-1157.2001.416800.x · PMID 11580761
45. Other Could Depakote cause Mydriasis. 18 November 2014
46. Journal / agency Bilo L, Meo R. Polycystic ovary syndrome in women using valproate: a review. Gynecological Endocrinology. October 2008. doi:10.1080/09513590802288259 · PMID 19012099
47. Journal / agency Chukwu J, Delanty N, Webb D, Cavalleri GL. Weight change, genetics and antiepileptic drugs. Expert Review of Clinical Pharmacology. January 2014. doi:10.1586/17512433.2014.857599 · PMID 24308788
48. Journal / agency Buoli M, Serati M, Botturi A, Altamura AC. The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data. Drugs in R&D. March 2018. doi:10.1007/s40268-017-0224-6 · PMID 29260458 · PMC5833908
49. Journal / agency Gruppuso PA, Ahmed R, Adashi EY. Valproate Teratogenicity: A Moving Target. Obstetrics and Gynecology. September 2022. doi:10.1097/AOG.0000000000004893 · PMID 35926210
50. Journal / agency Smolinski NE, Sarayani A, Thai TN, Jugl S, Ewig CL, Winterstein AG. Prenatal Exposure to Valproic Acid Across Various Indications for Use. JAMA Network Open. May 2024. doi:10.1001/jamanetworkopen.2024.12680 · PMID 38776082 · PMC11112441
51. Other Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): review by two specialists is required for initiating valproate but not for male patients already taking valproate
52. Journal / agency Sztajnkrycer MD. Valproic acid toxicity: overview and management. Journal of Toxicology. Clinical Toxicology. 2002. doi:10.1081/CLT-120014645 · PMID 12475192
53. Journal / agency Patsalos PN, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Therapeutic Drug Monitoring. February 2013. doi:10.1097/FTD.0b013e31827c11e7 · PMID 23288091
54. Journal / agency Thanacoody RH. Extracorporeal elimination in acute valproic acid poisoning. Clinical Toxicology. August 2009. doi:10.1080/15563650903167772 · PMID 19656009
55. Other R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1622–1626
56. Journal / agency Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?. Critical Care. October 2005. doi:10.1186/cc3742 · PMID 16277730 · PMC1297603
57. Journal / agency Mock CM, Schwetschenau KH. Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. American Journal of Health-System Pharmacy. January 2012. doi:10.2146/ajhp110049 · PMID 22180549
58. Journal / agency Matsuoka M, Igisu H. Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia. Biochemical Pharmacology. July 1993. doi:10.1016/0006-2952(93)90360-9 · PMID 8347126
59. Journal / agency Herzog AG, Farina EL, Blum AS. Serum valproate levels with oral contraceptive use. Epilepsia. June 2005. doi:10.1111/j.1528-1167.2005.00605.x · PMID 15946343
60. Journal / agency Kay HY, Greene DL, Kang S, Kosenko A, Hoshi N. M-current preservation contributes to anticonvulsant effects of valproic acid. The Journal of Clinical Investigation. October 2015. doi:10.1172/JCI79727 · PMID 26348896 · PMC4607138
61. Journal / agency Chang P, Walker MC, Williams RS. Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid. Neurobiology of Disease. February 2014. doi:10.1016/j.nbd.2013.10.017 · PMID 24148856 · PMC3898270
62. Journal / agency Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology. March 2010. doi:10.1038/npp.2009.197 · PMID 20010553 · PMC3055373
63. Journal / agency Wagner JM, Hackanson B, Lübbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clinical Epigenetics. December 2010. doi:10.1007/s13148-010-0012-4 · PMID 21258646 · PMC3020651
64. Journal / agency Lagace DC, O'Brien WT, Gurvich N, Nachtigal MW, Klein PS. Valproic acid: how it works. Or not. Clinical Neuroscience Research. 2004. doi:10.1016/j.cnr.2004.09.013
65. Journal / agency Sakai K, Hara K, Tanemura K. Testicular histone hyperacetylation in mice by valproic acid administration affects the next generation by changes in sperm DNA methylation. PLOS ONE. 3 September 2023. doi:10.1371/journal.pone.0282898 · PMID 36893188 · PMC9997898
66. Journal / agency Kostrouchová M, Kostrouch Z, Kostrouchová M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biologica. 2007. doi:10.14712/fb2007053020037 · PMID 17448293
67. Journal / agency Chiu CT, Wang Z, Hunsberger JG, Chuang DM. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacological Reviews. January 2013. doi:10.1124/pr.111.005512 · PMID 23300133 · PMC3565922
68. Journal / agency Death AK, McGrath KC, Handelsman DJ. Valproate is an anti-androgen and anti-progestin. Steroids. December 2005. doi:10.1016/j.steroids.2005.07.003 · PMID 16165177
69. Other Wyllie E, Cascino GD, Gidal BE, Goodkin HP. Wyllie's Treatment of Epilepsy: Principles and Practice. 17 February 2012
70. Journal / agency Uchida H, Maruyama T, Arase T, Ono M, Nagashima T, Masuda H, Asada H, Yoshimura Y. Histone acetylation in reproductive organs: Significance of histone deacetylase inhibitors in gene transcription. Reproductive Medicine and Biology. June 2005. doi:10.1111/j.1447-0578.2005.00101.x · PMID 29662388 · PMC5891791
71. Journal / agency Isojärvi JI, Taubøll E, Herzog AG. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs. 2005. doi:10.2165/00023210-200519030-00003 · PMID 15740176
72. Other Austria-Codex. 2021
73. Other Angewandte Arzneimitteltherapie. 2001
74. Other Valproate. Accessed 6 August 2021 Drugs.com pro valproate
75. Harm reduction site Valproic Acid. 31 August 2017
76. Journal / agency Treadwell JR, Wu M, Tsou AY. Management of Infantile Epilepsies. October 2022. doi:10.23970/ahrqepccer252 · PMID 36383706
77. Journal / agency Burton BS. On the propyl derivatives and decomposition products of ethylacetoacetate. Am. Chem. J. 1882
78. Journal / agency Meunier H, Carraz G, Neunier Y, Eymard P, Aimard M. Pharmacodynamic properties of N-dipropylacetic acid. Therapie. 1963. PMID 13935231
79. Journal / agency Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002. doi:10.2165/00023210-200216100-00004 · PMID 12269862
80. Journal / agency Henry TR. The history of valproate in clinical neuroscience. Psychopharmacology Bulletin. 2003. doi:10.64719/pb.7071 · PMID 14624229
81. Journal / agency Angus-Leppan H, Arkell R, Watkins L, Heaney D, Cooper P, Shankar R. New valproate regulations, informed choice and seizure risk. Journal of Neurology. August 2024. doi:10.1007/s00415-024-12436-8 · PMID 38896265 · PMC11319429
82. Other Valproate – reproductive risks. 2025-09-23
83. Journal / agency Bellas L, Català M, Burn E, Guo Y, Du M, Verhamme K, Fridgeirsson E, Duarte-Salles T, Kauko T, Kronqvist E, Brash JT, Seager S, Prieto-Alhambra D, Jödicke AM, Prats-Uribe A. Secular Trends in the Use of Valproate-Containing Medicines in Women of Childbearing Age in Europe: A Multinational DARWIN EU Network Study. Pharmacoepidemiology and Drug Safety. October 2025. doi:10.1002/pds.70232 · PMID 41099219 · PMC12529455
84. Other Jean-Marc Laurent, premier « papa Dépakine » à porter plainte. 18 March 2026
85. Other Un premier « papa Dépakine » saisit la justice pour « mise en danger » de sa fille. 18 March 2026
86. Other Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines. 2009
87. Journal / agency Zhang CQ, Li HY, Wan Y, Bai XY, Gan L, Wang J, Sun HB. Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials. Frontiers in Pharmacology. 2022-04-05. doi:10.3389/fphar.2022.811017 · PMID 35479307 · PMC9037144
88. Other 丙戊酸镁片（湖南湘中）
89. Other 丙戊酸镁缓释片（神泰）
90. Other Martindale: The Complete Drug Reference
91. Journal / agency Depakene- valproic acid capsule, liquid filled. 19 September 2019
92. Other Depakin - Banca Dati Farmaci dell'AIFA. 6 June 2023
93. Other Australian product information epilim (sodium valproate) crushable tablets, enteric-coated tablets, syrup, liquid. 15 April 2020
94. Other Sodium valproate -- Pharmaceutical Schedule
95. Other South African Electronic Package Inserts: Convulex
96. Other Malaysian Package Inserts: Epilim

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.